Author Archives: Joana Fernandes, PhD

Mitoconix Bio Obtains $20 Million To Continue Developing Huntington’s Therapy MTC-1203

Mitoconix Bio has secured $20 million in financing to continue developing MTC-1203 as a treatment for mitochondrial impairment in Huntington’s and Parkinson’s diseases. Several pharmaceutical companies and medical-related venture-capital funds participated in the financing. They include Aril Bioscience, OrbiMed, Remiges Ventures and the Dementia Discovery Fund. “We are very…